Univariate analysis showed that patients with HCC who overexpressed ZEB2 also exhibited a longer survival time (mean survival time, 57.6 months) than patients with HCC who normally expressed ZEB2 (mean, 42.5 months; P = 0.001, log-rank test, Table 2, Figure 4B). This evidence concerns the gene ZEB2 and hepatocellular carcinoma.